CurrentRheuma — Lupus & antiphospholipid syndrome

Measurement of kidney disease in a novel multidomain treatment response measure for SLE clinical trials

2026-11-13T11:15:45.584Z

Guideline or statement · Lupus Sci Med, 2026.

Real-world discontinuation of immunosuppressive therapy after proliferative lupus nephritis: the overlooked impact of non-adherence (MASSILUP-WIN)

2026-11-13T11:15:45.584Z

Cohort study · Lupus Sci Med, 2026.

Risk-stratified effectiveness of direct oral anticoagulants versus vitamin K antagonists in thrombotic antiphospholipid syndrome: a prospective cohort study

2026-11-13T11:15:45.584Z

Cohort study · Lupus Sci Med, 2026.

Screening for Neoehrlichia mikurensis and other emerging tick-borne pathogens in Swedish patients with systemic lupus erythematosus receiving B-cell-targeted therapies

2026-11-12T17:15:39.386Z

Research article · Scand J Rheumatol, 2026.

Longitudinal trends in vaccination uptake and respiratory infection burden in systemic lupus erythematosus: a population-based cohort study

2026-11-12T12:15:58.454Z

Cohort study · Rheumatology (Oxford), 2026.

Social and Structural Forces Shaping Reproductive Decision‐Making in Hispanic Women with Systemic Lupus Erythematosus: A Qualitative Study

2026-11-12T11:15:54.044Z

Research article · Arthritis Care Res (Hoboken), 2026.

Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index

2026-11-11T17:15:37.180Z

Research article · Arthritis Care Res (Hoboken), 2026.

Anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome: clinical associations and methodological heterogeneity—a scoping review

2026-11-11T05:17:20.747Z

Research article · Semin Arthritis Rheum, 2026.

Eltrombopag in the treatment of immune thrombocytopenia secondary to SLE: A double-edged sword

2026-11-10T23:15:28.186Z

Cohort study · Lupus, 2026.

CD163+ macrophage infiltration reflects disease activity and early treatment response in lupus nephritis

2026-11-09T17:15:24.911Z

Cohort study · Clin Exp Rheumatol, 2025.

Obesity-exacerbated lupus via leptin-induced putrescine depletion and Tfh cell hyperactivation

2026-11-09T17:15:24.911Z

Research article · Clin Exp Rheumatol, 2026.

Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

2026-11-09T09:15:57.425Z

Randomized controlled trial · Lancet Rheumatol, 2026.

Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study

2026-11-06T09:16:48.334Z

Secondary analysis · Lupus Sci Med, 2026.

Maternal and neonatal outcomes in SLE: comparison of 430 pregnancies from the French GR2 study with 1720 pregnancies from French perinatal surveys

2026-11-06T09:16:48.334Z

Cohort study · Lupus Sci Med, 2026.

Pulmonary function, functional capacity and physical activity in patients with SLE: a cross-sectional study

2026-11-06T09:16:48.334Z

Cross-sectional study · Lupus Sci Med, 2026.

Catastrophic antiphospholipid syndrome after COVID-19 mRNA vaccination: A case report

2026-11-06T05:15:34.451Z

Research article · Lupus, 2026.

Patient selection for advanced B-cell-targeted therapy trials in systemic lupus erythematosus

2026-11-05T17:15:34.474Z

Cohort study · Lupus, 2026.

Advanced practice nursing and nurse-led models in systemic lupus erythematosus: A patient organisation-informed narrative review

2026-11-05T13:24:18.717Z

Research article · Lupus, 2026.

Articular involvement in antiphospholipid syndrome: Clinical, laboratory, and imaging characterization

2026-11-05T13:24:18.717Z

Cross-sectional study · Lupus, 2026.

Biopsychosocial factors associated with body image in Brazilian women with Systemic Lupus Erythematosus

2026-11-05T13:24:18.717Z

Cross-sectional study · Lupus, 2026.

Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis

2026-11-05T13:24:18.717Z

Meta-analysis · Semin Arthritis Rheum, 2026.

Colchicine usage and recurrent pericarditis in patients with systemic lupus erythematosus

2026-11-05T13:24:18.717Z

Cohort study · Lupus, 2026.

Comorbidity burden and its impact on physical functioning and activities of daily living in patients with systemic lupus erythematosus

2026-11-05T13:24:18.717Z

Cross-sectional study · Rheumatology (Oxford), 2026.

Development and validation of the SLE Disease Activity Questionnaire (SLEDAQ)

2026-11-05T13:24:18.717Z

Diagnostic or prognostic study · Lupus Sci Med, 2026.

Differentiation and Pathological Significance of Tissue‐Resident Memory‐Like CD8 + T Cells in Systemic Lupus Erythematosus

2026-11-05T13:24:18.717Z

Research article · Arthritis Rheumatol, 2026.

Disease activity and patient‐perceived health: associations with the Patient Acceptable Symptom State (PASS) in a large multicenter systemic lupus erythematosus cohort

2026-11-05T13:24:18.717Z

Cohort study · Arthritis Care Res (Hoboken), 2026.

Effect of dapagliflozin on renal response in patients with biopsy-confirmed lupus nephritis receiving stable maintenance immunosuppression and renin–angiotensin system inhibition: protocol for the multicentre randomised DAPA-LN trial

2026-11-05T13:24:18.717Z

Trial design · Lupus Sci Med, 2026.

Effect of ethnicity on response to treatment escalation in patients with systemic lupus erythematosus from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a longitudinal cohort study

2026-11-05T13:24:18.717Z

Cohort study · Lancet Rheumatol, 2026.

Effect of upadacitinib and ABBV-599 on biomarkers in SLE: results from the phase 2 SLEek study

2026-11-05T13:24:18.717Z

Randomized controlled trial · Lupus Sci Med, 2026.

Extra-renal disease patterns in lupus nephritis: clinical and serological activity confers increased risk of renal flares and damage accrual

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

First trimester exposure to hydroxychloroquine during pregnancy and major congenital malformations: a systematic review and meta-analysis

2026-11-05T13:24:18.717Z

Meta-analysis · RMD Open, 2026.

Impact of deucravacitinib on arthritis in patients with systemic lupus erythematosus: results from the phase II PAISLEY SLE study

2026-11-05T13:24:18.717Z

Secondary analysis · Lupus Sci Med, 2026.

Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in daily clinical practice: A prospective study of 125 patients in India

2026-11-05T13:24:18.717Z

Diagnostic or prognostic study · Lupus, 2026.

Serological and clinical outcomes of rituximab in antiphospholipid syndrome with or without SLE: a retrospective single-centre cohort

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Systemic Immune-Inflammation Index (SII) correlates with disease activity but not with interferon-associated chemokines in SLE

2026-11-05T13:24:18.717Z

Cross-sectional study · Lupus Sci Med, 2026.

Threshold of Hydroxychloroquine Dose Reduction Associated with Flare in Quiescent Systemic Lupus Erythematosus

2026-11-05T13:24:18.717Z

Cohort study · Arthritis Care Res (Hoboken), 2026.

Transcriptomic effects of hydroxychloroquine in CD4+ T cells from patients with systemic lupus erythematosus: An exploratory pilot study

2026-11-05T13:24:18.717Z

Secondary analysis · Lupus, 2026.

Impact of pregnancy on organ damage in systemic lupus erythematosus: a multicentre study

2026-11-05T13:10:58.883Z

Research article · Lupus Sci Med, 2026.

Machine learning improves 10-year prediction of atherosclerotic plaque progression and cardiovascular events in systemic lupus erythematosus

2026-11-05T13:10:58.883Z

Diagnostic or prognostic study · Rheumatology (Oxford), 2026.

Macrophage activation syndrome is associated with high in-hospital mortality in patients with lupus

2026-11-05T13:10:58.883Z

Cohort study · Lupus, 2026.

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

2026-11-04T23:57:40.771Z

Randomized controlled trial · Lancet, 2023. SRI-4 response, week 52: Baricitinib 4 mg 121 (47%) · Baricitinib 2 mg 120 (46%) · Placebo 116 (46%)

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

2026-11-04T23:57:40.771Z

Randomized controlled trial · Lancet, 2023. SRI-4 response, week 52: Baricitinib 4 mg 142 (57%) · Baricitinib 2 mg 126 (50%) · Placebo 116 (46%)

Maternal and infant outcomes of pregnancy associated with anti-SSA/RO antibodies: a systematic review and meta-analysis

2026-11-04T23:51:38.466Z

Meta-analysis · Pediatr Rheumatol Online J, 2023. Maternal: termination of pregnancy 4%

Adherence to antimalarials and glucocorticoids treatment and its association with self-reported disease activity in systemic lupus erythematosus patients

2026-11-04T23:48:14.847Z

Cross-sectional study · Lupus, 2022. Prevalence of non-adherence: Non-adherence to antimalarials 10.67%

Alexithymia in systemic lupus erythematosus: A cross sectional study in a Brazilian sample

2026-11-04T23:48:14.847Z

Cross-sectional study · Lupus, 2022. Prevalence of alexithymia (TAS-26): Alexithymia 55.9%

An ecological approach to understanding and addressing health inequities of systemic lupus erythematosus

2026-11-04T23:48:14.847Z

Research article · Lupus, 2023. Ecological model adapted to illustrate the connection between systems issues and SLE health outcomes

Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE

2026-11-04T23:48:14.847Z

Cohort study · Lupus, 2023. Anti-SARS-CoV-2 antibody levels, 4-8 weeks after second dose — SLE vs HC; p < 0.001; Antibody levels lower in SLE

Assessment of bidirectional relationships between systemic lupus erythematosus and anxiety disorder: A two-sample Mendelian randomization study

2026-11-04T23:48:14.847Z

Research article · Lupus, 2023. Genetically predicted SLE → anxiety disorder risk (IVW), OR 1.000 (95% CI 0.992 to 1.008, p =.997)

Association between early immunophenotypic changes and therapeutic response of belimumab in patients with systemic lupus erythematosus

2026-11-04T23:48:14.847Z

Mechanistic study · Lupus, 2022. Therapeutic response at 6 months by lower PC2 (increased BAFF receptor (BAFF-R) expression, decreased % naïve B cells): Lower PC2 associated with subsequent therapeutic response, OR 5.3 (95% CI 1.2-24, p = .031)

Association between serum uric acid level and systemic lupus erythematosus kidney outcome: An observational study in Southern Chinese population and a meta-analysis

2026-11-04T23:48:14.847Z

Meta-analysis · Lupus, 2022. LN progression — Increased serum uric acid level (continuous variable): HR 1.003 (95% CI 1.001-1.005); Cox proportional hazard regression model